RxDoctor Payments Data

Aimee French, MD

Critical Care Medicine · Riverside, CANPI 1730376179

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 114 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$866
  • Insmed, Inc.$328
  • Sunovion Pharmaceuticals Inc.$192
  • AstraZeneca$171
  • Genentech USA, Inc.$101
  • Verona Pharma, Inc.$64
  • plus $210 from 9 others

What the payments were for

  • Food & beverage$1,80093%
  • Education$1327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,932 in reported general payments places this provider in the 70th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$274,453
Medicare patients
441
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat17$216,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$46,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$23,584
Budesonide32$8,153
Breo ElliptaFluticasone/Vilanterol17$7,203
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,863
Arformoterol Tartrate18$5,857
Levalbuterol Hcl88$5,750
Scopolamine28$3,252
Wixela InhubFluticasone Propion/Salmeterol17$2,874
Acetylcysteine12$2,743
SymbicortBudesonide/Formoterol Fumarate11$2,637
Albuterol Sulfate HfaAlbuterol Sulfate74$2,045
Montelukast Sodium182$1,597
Ipratropium Bromide40$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$18$216,86817 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$866$60,63795 claims
AstraZenecaBreztri Aerosphere, Symbicort$171$26,22244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →